A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetes

Overview of attention for article published in BMC Endocrine Disorders, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 2 news stories from 2 outlets.

GlobeNewswire 2018-09-24 LAWRENCE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc.

LAWRENCE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the "Company" or "BTI") (OTCQB:BTHE), an…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.